The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Long-term follow-up of TRANSFORM: liso-cel versus SOC for R/R LBCL
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, discusses first results from long-term follow-up of the TRANSFORM trial (NCT03575351) of lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Kamdar notes that the long-term follow-up protocol showed high progression-free survival and overall survival rates for patients treated with liso-cel, demonstrating the curative potential of this agent. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
